Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutations in Patients With Advanced or Metastatic NSCLC at Front-line and Progression
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 463
- 试验地点
- 1
- 主要终点
- Evaluation of the EGFR mutation
研究概览
简要总结
Evaluate molecular testing and treatment patterns for EGFR mutation in two different cohorts of stage IV NSCLC, at diagnosis (treatment naïve) and at the moment of progression to EGFR-TKIs. This study is non-indication seeking (NIS), descriptive in nature and does not attempt to test any specific a priori hypotheses.
详细描述
Objectives and Hypotheses : The objectives of this study are to evaluate molecular testing and treatment patterns for EGFR mutation in two different cohorts of stage IV NSCLC, at diagnosis (treatment naïve) and at the moment of progression to EGFR-TKIs. This study is non-indication seeking (NIS), descriptive in nature and does not attempt to test any specific a priori hypotheses. The following study objectives will be assessed:
Primary Objectives
- To estimate parameters associated with molecular testing patterns at diagnosis of advance disease and progression to EGFR TKIs
- To estimate parameters associated with treatment patterns at frontline and at progression to a EGFR TKI therpay
Secondary Objectives
- To estimate the rate of central nervous system (CNS) metastases at diagnosis and after disease progression in EGFR+ NSCLC patients
- To estimate parameters associated with biopsy related complications
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Evaluation of the EGFR mutation
时间窗: Clinical charts from January 2013-december 2017
Test used to determine EGFRm, registered in clinical charts
次要结局
未报告次要终点